biological source
mouse
conjugate
unconjugated
antibody form
purified from hybridoma cell culture
antibody product type
primary antibodies
clone
OSTF21, monoclonal
form
buffered aqueous solution
mol wt
antigen ~28 kDa
species reactivity
rat, monkey, mouse, bovine, human
packaging
antibody small pack of 25 μL
concentration
~1.5 mg/mL
technique(s)
indirect immunofluorescence: 10-20 μg/mL using MCF-7 cells, western blot: 0.5-1 μg/mL using NRK cell extracts
isotype
IgG2b
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... OSTF1(26578)
mouse ... Ostf1(20409)
rat ... Ostf1(259275)
General description
Monoclonal Anti-OSTF1 (mouse IgG2b isotype) is derived from the hybridoma OSTF21 produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with a synthetic peptide.The osteoclast-stimulating factor (OSF or OSTF1) contains a short proline-rich N-terminal region, an SH3 domain, three ankyrin repeats and an aspartate rich C-terminal region. It is a novel 28 kDa intracellular protein predominantly expressed in osteoclast (OCL). The OSTF1 gene is mapped to human chromosome 9q21.13.
Application
Anti-OSTF1 antibody, Mouse monoclonal is suitable for immunoblotting and immunofluorescence.
Biochem/physiol Actions
Monoclonal Anti-OSTF1 recognizes human, monkey, bovine, rat, and mouse OSTF1.
Osteoclast-stimulating factor (OSF or OSTF1) is potentially involved in protein-protein interactions. It supports bone resorption by cellular signal transduction cascade. OSTF1 induces osteoclast (OCL) bone formation by its SH3 domain interacting with spinal muscular atrophy disease determining gene product, survival motor neuron (SMN). The OSF SH3-SMN interaction might be significant in congenital bone fractures associated with type I spinal muscular atrophy disease. Repressed, OSF-SH3 domain interaction with its protein partners might cause reduced bone resorption by OCL. This prevents the bone loss that is associated with many bone diseases, such as osteoporosis, periodontal disease, Paget′s disease, estrogen deficiency, inflammatory bone loss, hyperparathyroidism and bone malignancy.
Physical form
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
Preparation Note
Store at –20 °C. For continuous use, the product may be stored at 2–8 °C for up to one month. For extended storage, freeze in working aliquots at –20 °C. Repeated freezing and thawing, or storage in “frost-free” freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples should be discarded if not used within 12 hours.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Still not finding the right product?
试用我们的 产品选型工具 工具缩小选择范围
存储类别
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
相关内容
Instructions
Structure of the SH3 domain of human osteoclast-stimulating factor at atomic resolution
Chen L, et al.
Acta Crystallographica Section F, Structural Biology and Crystallization Communications, 62(9), 844-844 (2006)
RORB gene and 9q21. 13 microdeletion: report on a patient with epilepsy and mild intellectual disability
Baglietto MG, et al.
European Journal of Medical Genetics, 57(1), 44-46 (2014)
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SAB4200092-25UL | 04061837875359 |
| SAB4200092-200UL | 04061836270568 |